Teva Pharmaceutical Industries (NYSE:TEVA) Reaches New 52-Week High at $14.47

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Get Free Report) hit a new 52-week high during trading on Monday . The stock traded as high as $14.47 and last traded at $14.36, with a volume of 1677410 shares traded. The stock had previously closed at $14.25.

Analyst Upgrades and Downgrades

Several brokerages recently commented on TEVA. JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from an "underweight" rating to a "neutral" rating and set a $14.00 price target for the company in a research report on Friday, March 8th. The Goldman Sachs Group increased their price objective on shares of Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the stock a "neutral" rating in a research report on Monday, February 5th. Barclays increased their price objective on shares of Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the stock an "overweight" rating in a research report on Monday, February 5th. HSBC started coverage on shares of Teva Pharmaceutical Industries in a research report on Monday, December 18th. They issued a "buy" rating and a $13.00 price objective for the company. Finally, Piper Sandler raised shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and increased their price objective for the stock from $12.00 to $19.00 in a research report on Monday, February 12th. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $13.78.

Teva Pharmaceutical Industries Stock Down 0.4 %

The company has a market capitalization of $15.92 billion, a price-to-earnings ratio of -30.21, a PEG ratio of 1.65 and a beta of 1.05. The stock's fifty day simple moving average is $13.28 and its two-hundred day simple moving average is $11.07. The company has a debt-to-equity ratio of 2.23, a current ratio of 1.02 and a quick ratio of 0.69.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings data on Wednesday, January 31st. The company reported $0.98 earnings per share for the quarter, topping analysts' consensus estimates of $0.73 by $0.25. Teva Pharmaceutical Industries had a negative net margin of 3.33% and a positive return on equity of 34.90%. The business had revenue of $4.46 billion for the quarter, compared to analysts' expectations of $3.97 billion. On average, sell-side analysts predict that Teva Pharmaceutical Industries Limited will post 2.28 earnings per share for the current fiscal year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, EVP Mark Sabag sold 100,000 shares of the firm's stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $13.52, for a total transaction of $1,352,000.00. Following the completion of the transaction, the executive vice president now owns 382,590 shares in the company, valued at approximately $5,172,616.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Teva Pharmaceutical Industries news, CAO Amir Weiss sold 31,766 shares of the firm's stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $12.37, for a total value of $392,945.42. Following the completion of the transaction, the chief accounting officer now directly owns 10,676 shares in the company, valued at $132,062.12. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Mark Sabag sold 100,000 shares of the business's stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $13.52, for a total transaction of $1,352,000.00. Following the transaction, the executive vice president now directly owns 382,590 shares in the company, valued at $5,172,616.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 390,738 shares of company stock valued at $5,132,766. Company insiders own 0.62% of the company's stock.

Institutional Trading of Teva Pharmaceutical Industries

A number of institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. lifted its stake in Teva Pharmaceutical Industries by 3.7% in the first quarter. BlackRock Inc. now owns 41,648,716 shares of the company's stock valued at $391,081,000 after acquiring an additional 1,494,814 shares during the last quarter. Phoenix Holdings Ltd. lifted its stake in Teva Pharmaceutical Industries by 2.3% in the third quarter. Phoenix Holdings Ltd. now owns 34,481,692 shares of the company's stock valued at $351,713,000 after acquiring an additional 778,282 shares during the last quarter. Lingotto Investment Management LLP lifted its stake in Teva Pharmaceutical Industries by 1.8% in the fourth quarter. Lingotto Investment Management LLP now owns 34,457,656 shares of the company's stock valued at $359,738,000 after acquiring an additional 607,800 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd lifted its stake in shares of Teva Pharmaceutical Industries by 7.1% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 32,804,131 shares of the company's stock worth $342,788,000 after buying an additional 2,188,212 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. lifted its stake in shares of Teva Pharmaceutical Industries by 6.9% in the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 28,919,540 shares of the company's stock worth $301,920,000 after buying an additional 1,860,000 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.